Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
40 Items
Title  Creator  Group name  Publishing year 
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial Mazard et al. EquipeMY 2024-06-17
Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non-small cell lung cancers Sauvageot et al. EquipeMY 2024-07-01
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity Alcaraz et al. EquipeELC 2022-11-08
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects Leenhardt et al. EquipeCTCS 2022-04-11
In situ hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type?1 in formalin?fixed paraffin?embedded breast cancer specimens Boissière-Michot et al. EquipeCTCS 2022-06
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer Bobrie et al. EquipeNB 2022-10-03
Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer Darlix et al. EquipeCTCS 2021-10-15
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers Jacot et al. EquipeELC 2021-12-01
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers Boissière-Michot et al. EquipeCTCS 2021-05-12
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer Boissière-Michot et al. EquipeCTCS 2021-02-12
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment Alcaraz et al. EquipeCTCS 2021
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening Tanos et al. EquipeCTCS 2020-09
Diversity of Tumor-Infiltrating, ?? T-Cell Abundance in Solid Cancers Chabab et al. EquipeNB Jun 24, 2020
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer Fabbro et al. EquipeCTCS 2020-08-05
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival Mansouri et al. EquipeCTCS 2020-05-15
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer Jacot et al. EquipeELC 2020-08-01
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer Jacot et al. EquipeMY 2020-03-30
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy Mazard et al. EquipeMY May 10, 2019
Quantifying circulating cell-free DNA in humans Meddeb et al. EquipeMY Mar 26, 2019
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples Ho-Pun-Cheung et al. EquipeCTCS Dec 03, 2019
Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial Boige et al. EquipeMY May 20, 2019
Complementary and Alternative Medicine in Patients With Breast Cancer: Exploratory Study of Social Network Forum Data Lognos et al. EquipeAD Nov 27, 2019
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection Viala et al. EquipeCG Mar 06, 2018
Reconciliation of patient/doctor vocabulary in a structured resource Tapi Nzali et al. EquipeMY Jan 01, 2018
12>>>
40 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés